Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. (VNDA) Healthcare & Pipeline Overview

Vanda Pharmaceuticals Inc. develops and commercializes therapies for unmet medical needs, focusing on sleep disorders and schizophrenia. With products like HETLIOZ and Fanapt, the company operates in the competitive biotechnology sector, pursuing treatments for conditions such as jet lag, atopic dermatitis, and psychiatric disorders across the United States, Europe, and Israel.

What Is the Investment Thesis for VNDA?

Vanda Pharmaceuticals presents a mixed investment thesis. The company's focus on niche markets with high unmet needs, such as non-24-hour sleep-wake disorder and gastroparesis, offers potential for revenue growth, especially if pipeline products like Tradipitant gain approval. The gross margin of 92.5% indicates strong pricing power. However, the negative profit margin of -110.0% raises concerns about profitability and operational efficiency. Upcoming clinical trial results for Tradipitant in atopic dermatitis and gastroparesis could serve as catalysts. Investors should closely monitor the company's ability to manage expenses and achieve profitability while advancing its pipeline. The company's beta of 0.71 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

VNDA Key Highlights

• Market capitalization of $375.55M, reflecting its valuation in the biopharmaceutical market.
• Gross margin of 92.5%, indicating strong pricing power and efficient cost management in product sales.
• Negative profit margin of -110.0%, signaling potential concerns about profitability and operational efficiency.
• Beta of 0.71, suggesting lower volatility compared to the broader market, which may appeal to risk-averse investors.
• Focus on niche markets with high unmet needs, such as non-24-hour sleep-wake disorder and gastroparesis, offering potential for revenue growth.

Who Are VNDA's Competitors?

VNDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VNDA's Key Strengths?

• Marketed products addressing unmet medical needs (HETLIOZ, Fanapt).
• Robust pipeline of products in various stages of development.
• High gross margin (92.5%) indicating strong pricing power.
• Global presence with sales in the United States, Europe, and Israel.

What Are VNDA's Weaknesses?

• Negative profit margin (-110.0%) raising concerns about profitability.
• Reliance on a limited number of marketed products.
• Potential challenges in obtaining regulatory approvals for pipeline products.
• Competition from other pharmaceutical companies in the same therapeutic areas.

What Could Drive VNDA Stock Higher?

• Clinical trial results for Tradipitant in atopic dermatitis.
• Clinical trial results for Tradipitant in gastroparesis.
• Regulatory review of HETLIOZ for jet lag disorder.
• Development of Fanapt long-acting injectable.
• Advancement of VTR-297 in clinical trials for hematologic malignancies.

What Are the Key Risks for VNDA?

• Financial-distress signal — its Altman Z-Score of -0.17 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-61.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approvals for pipeline products.
• Patent expirations on key products leading to generic competition.
• Competition from other pharmaceutical companies.
• Product liability claims.
• Dependence on a limited number of marketed products.

What Are the Growth Opportunities for VNDA?

• Tradipitant for Atopic Dermatitis: Vanda is developing Tradipitant for the treatment of atopic dermatitis, a chronic inflammatory skin condition. The global atopic dermatitis market is projected to reach billions of dollars, driven by the high prevalence of the condition and the need for more effective treatments. Positive clinical trial results and subsequent regulatory approval could significantly expand Vanda's revenue base. The timeline for potential approval is dependent on clinical trial outcomes and regulatory review processes.
• Tradipitant for Gastroparesis: Vanda is also investigating Tradipitant for the treatment of gastroparesis, a condition characterized by delayed gastric emptying. The gastroparesis market represents a significant opportunity, with a growing patient population and limited treatment options. Successful development and commercialization of Tradipitant for this indication could generate substantial revenue for Vanda. Clinical trials are ongoing, and regulatory submissions would follow positive results.
• HETLIOZ for Jet Lag Disorder: Vanda is exploring the use of HETLIOZ for the treatment of jet lag disorder. The increasing prevalence of international travel has created a growing market for jet lag remedies. If approved for this indication, HETLIOZ could capture a share of this market, providing a new revenue stream for Vanda. Clinical trials are underway to evaluate the efficacy of HETLIOZ in treating jet lag.
• Fanapt Long-Acting Injectable: Vanda is developing a long-acting injectable formulation of Fanapt for the treatment of schizophrenia. This formulation could offer improved patient compliance and convenience compared to oral tablets, potentially increasing market share and revenue. The long-acting injectable market for antipsychotics is substantial, and a successful product launch could contribute significantly to Vanda's growth. Development and regulatory timelines are key considerations.
• VTR-297 for Hematologic Malignancies: Vanda is developing VTR-297, a histone deacetylase inhibitor, for the treatment of hematologic malignancies. The oncology market is a major area of pharmaceutical research and development, with a high demand for novel therapies. If VTR-297 proves effective and receives regulatory approval, it could become a valuable asset in Vanda's portfolio. Clinical trials are ongoing to assess the safety and efficacy of VTR-297.

What Opportunities Does VNDA Have?

• Expansion of HETLIOZ into new indications (jet lag disorder, etc.).
• Successful development and commercialization of Tradipitant.
• Growth in the market for long-acting injectable antipsychotics.
• Potential partnerships or collaborations to expand market reach.

What Threats Does VNDA Face?

• Patent expirations on key products.
• Generic competition eroding market share.
• Unfavorable regulatory decisions.
• Product liability claims.

What Are VNDA's Competitive Advantages?

• Patented pharmaceutical products provide market exclusivity.
• Specialized focus on niche markets with high unmet needs.
• Established relationships with healthcare providers and pharmacies.
• Proprietary drug development platform and expertise.

What Does VNDA Do?

Vanda Pharmaceuticals Inc. was founded in 2002 and is headquartered in Washington, D.C. The company is a biopharmaceutical entity dedicated to addressing high unmet medical needs through the development and commercialization of innovative therapies. Vanda's marketed products include HETLIOZ (tasimelteon), used for treating non-24-hour sleep-wake disorders, a condition prevalent among blind individuals, and Fanapt (iloperidone) oral tablets, prescribed for the treatment of schizophrenia. Beyond its current offerings, Vanda has a robust pipeline of products in various stages of development. These include formulations of HETLIOZ targeting jet lag disorder, Smith-Magenis syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. The company is also developing a long-acting injectable formulation of Fanapt for schizophrenia and Tradipitant (VLY-686), a neurokinin-1 receptor antagonist, for conditions like atopic dermatitis, gastroparesis, and motion sickness. Additionally, Vanda is exploring VTR-297, a histone deacetylase inhibitor, for hematologic malignancies and other oncology indications. Other pipeline products include VQW-765 for psychiatric disorders, CFTR activators/inhibitors for dry eye and ocular inflammation, BPO-27 for secretory diarrhea, and VHX-896, an iloperidone metabolite. Vanda markets its products in the United States, Europe, and Israel, reflecting its global reach in addressing critical medical needs.

What Products and Services Does VNDA Offer?

• Develop and commercialize therapies for unmet medical needs.
• Market HETLIOZ for the treatment of non-24-hour sleep-wake disorders.
• Market Fanapt oral tablets for the treatment of schizophrenia.
• Develop HETLIOZ for jet lag disorder, Smith-Magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder.
• Develop Fanapt long-acting injectable for schizophrenia.
• Develop Tradipitant for atopic dermatitis, gastroparesis, and motion sickness.
• Explore VTR-297 for hematologic malignancies and oncology indications.
• Investigate VQW-765 for psychiatric disorders.

How Does VNDA Make Money?

• Develop and obtain regulatory approval for pharmaceutical products.
• Manufacture and market approved products directly or through partnerships.
• Generate revenue through product sales in the United States, Europe, and Israel.
• Invest in research and development to expand product pipeline.

What Industry Does VNDA Operate In?

Vanda Pharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The industry is driven by the increasing demand for novel therapies to address unmet medical needs. Vanda focuses on niche markets, differentiating itself from larger pharmaceutical companies that target broader patient populations. The competitive landscape includes companies developing treatments for sleep disorders, psychiatric conditions, and dermatological diseases. The biotechnology industry is expected to continue growing, driven by advancements in genomics, personalized medicine, and increasing healthcare expenditure.

Who Are VNDA's Key Customers?

• Patients with non-24-hour sleep-wake disorders.
• Patients with schizophrenia.
• Healthcare providers who prescribe Vanda's medications.
• Pharmacies that dispense Vanda's products.
• Hospitals and clinics that use Vanda's therapies.

How Vanda Pharmaceuticals Inc. Is Valued

Vanda Pharmaceuticals Inc. carries a market capitalization of $375.55M, placing it in the small-cap category. Relative to its peer group, VNDA's quantitative score of 15/100 is below the peer average of 76/100.

Company Profile

Vanda Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Washington, US. The company is led by CEO Mihael H. Polymeropoulos. VNDA has traded publicly since 2006.

ROE -61%Key Financial Metrics

Return on equity for Vanda Pharmaceuticals Inc. stands at -61.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -55.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -34.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -64.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Vanda Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.17 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Vanda Pharmaceuticals Inc. revenue of about $262.1M for fiscal 2026, with EPS near $-2.25. The estimate reflects 3 contributing analysts.

Net buyingInsider Activity

Over the past six months, Vanda Pharmaceuticals Inc. insiders filed 9 SEC Form 4 transactions — 1 sales and 8 purchases. On net that is roughly 361K shares acquired (about $0) — insiders putting money in tends to read as conviction.

VNDA Financials

VNDA Latest News

VNDA Analyst Consensus

VNDA MoonshotScore

Latest Vanda Pharmaceuticals Inc. Analysis

Vanda Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources